Literature DB >> 15031358

Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy.

Peter Stenvinkel1, Ulf Diczfalusy, Bengt Lindholm, Olof Heimbürger.   

Abstract

BACKGROUND: There is a high incidence of premature cardiovascular disease (CVD) in patients with end-stage renal disease (ESRD). Free radical-induced tissue damage is thought to play a major role in the pathogenesis of atherosclerosis, and there are several reports indicating an increased oxidative stress in ESRD. However, it is not well established that increased oxidative stress predicts cardiovascular mortality in ESRD. Plasmalogens, a group of phospholipids with a vinyl ether bond in the sn-1 position, are considered to be sensitive markers of oxidative stress.
METHODS: Cardiovascular and non-cardiovascular mortality was recorded (follow-up time 1860+/-94 days) in 105 ESRD patients (mean age 51+/-2 years) in whom the fasting ratio of the erythrocyte levels of plasmalogens (DMA 16/C16:0 and DMA 18/C18:0) had been determined at the start of renal replacement therapy (RRT). The prevalence of malnutrition (subjective global assessment), diabetes mellitus (DM), smoking habits and CVD was also determined.
RESULTS: Thirty-eight patients who died of CVD (0.066+/-0.003) had a significantly lower DMA 16/C16:0 ratio than 15 patients who died of non-cardiovascular causes (0.078+/-0.005; P<0.05) and 52 patients alive at follow-up (0.075+/-0.003; P<0.05). A Cox proportional hazard model analysis showed that a low (<median) DMA 16/C16:0 ratio at the start of RRT was associated (relative risk 1.50; confidence interval 1.07-2.16; P<0.05) with CVD mortality independently of age, gender, DM and CVD.
CONCLUSION: These results suggest that increased oxidative stress may be a risk factor for cardiovascular mortality in ESRD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15031358     DOI: 10.1093/ndt/gfh035

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  19 in total

Review 1.  Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrology (Carlton)       Date:  2009-06       Impact factor: 2.506

2.  Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial.

Authors:  Matthew B Rivara; Catherine K Yeung; Cassianne Robinson-Cohen; Brian R Phillips; John Ruzinski; Denise Rock; Lori Linke; Danny D Shen; T Alp Ikizler; Jonathan Himmelfarb
Journal:  Am J Kidney Dis       Date:  2016-12-04       Impact factor: 8.860

3.  Serum choline plasmalogens, particularly those with oleic acid in sn-2, are associated with proatherogenic state.

Authors:  Megumi Nishimukai; Ryouta Maeba; Yuya Yamazaki; Toru Nezu; Toshihiro Sakurai; Yuji Takahashi; Shu-Ping Hui; Hitoshi Chiba; Tomoki Okazaki; Hiroshi Hara
Journal:  J Lipid Res       Date:  2014-03-10       Impact factor: 5.922

4.  Metabolites Associated With Risk of Developing Mobility Disability in the Health, Aging and Body Composition Study.

Authors:  Rachel A Murphy; Steven Moore; Mary Playdon; Stephen Kritchevsky; Anne B Newman; Suzanne Satterfield; Hilsa Ayonayon; Clary Clish; Robert Gerszten; Tamara B Harris
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-01-01       Impact factor: 6.053

Review 5.  Cardiovascular risk in the peritoneal dialysis patient.

Authors:  Raymond T Krediet; Olga Balafa
Journal:  Nat Rev Nephrol       Date:  2010-06-22       Impact factor: 28.314

6.  Oxidative environment causes molecular remodeling in embryonic heart-a metabolomic and lipidomic fingerprinting analysis.

Authors:  Shairam Manickaraj; Deepak Thirumalai; Prashanth Manjunath; Viswanathan Sekarbabu; Sivasubramanian Jeganathan; Lakshmikirupa Sundaresan; Rajalakshmi Subramaniyam; Manivannan Jeganathan
Journal:  Environ Sci Pollut Res Int       Date:  2017-09-02       Impact factor: 4.223

7.  Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study.

Authors:  Rishikesh Mankidy; Pearson Wk Ahiahonu; Hong Ma; Dushmanthi Jayasinghe; Shawn A Ritchie; Mohamed A Khan; Khine K Su-Myat; Paul L Wood; Dayan B Goodenowe
Journal:  Lipids Health Dis       Date:  2010-06-14       Impact factor: 3.876

8.  Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial.

Authors:  Jonathan Himmelfarb; T Alp Ikizler; Charles Ellis; Pingsheng Wu; Ayumi Shintani; Sanjay Dalal; Mark Kaplan; Michel Chonchol; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2013-12-26       Impact factor: 10.121

9.  Human and great ape red blood cells differ in plasmalogen levels and composition.

Authors:  Ann B Moser; Steven J Steinberg; Paul A Watkins; Hugo W Moser; Krishna Ramaswamy; Kimberly D Siegmund; D Rick Lee; John J Ely; Oliver A Ryder; Joseph G Hacia
Journal:  Lipids Health Dis       Date:  2011-06-17       Impact factor: 3.876

10.  Plasma Metabolomic Signatures of Healthy Dietary Patterns in the Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Hyunju Kim; Cheryl Am Anderson; Emily A Hu; Zihe Zheng; Lawrence J Appel; Jiang He; Harold I Feldman; Amanda H Anderson; Ana C Ricardo; Zeenat Bhat; Tanika N Kelly; Jing Chen; Ramachandran S Vasan; Paul L Kimmel; Morgan E Grams; Josef Coresh; Clary B Clish; Eugene P Rhee; Casey M Rebholz
Journal:  J Nutr       Date:  2021-10-01       Impact factor: 4.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.